Moderna's mRNA-1020 universal flu vaccine showed 95% efficacy in a 48,000-participant Phase 3 trial across 40 countries.

Broad-Spectrum Protection

Targets conserved hemagglutinin protein in all influenza A and B strains. Protection lasts 3+ years, potentially requiring boosters only every 5 years.